$XBI $120.05 +0.56%
Covid Updates
$NVAX -0.3% Novavax Files for Interim Authorization of COVID-19 Vaccine in Singapore. source
Pipeline Updates
$SELB -12.9% Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia source
$CYDY +5.5% Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec. source
$SEEL -3.6% Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine. source
$AVRO +4.8% AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1. source
$KURA -15.5% Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia. source
$SAGE +0.7% Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. source
$HCM +3.3% HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy. source
Business Updates
$SUPN -0.3% Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals. source
Posted by FS
Comments